Financials

%ChgLast 12MReverse

	FY202312/31/2023	FY202412/31/2024	FY202512/31/2025	Last 12M03/31/2026
Cash and Cash Equivalents	52.2	62.5	60.5	90.9
Short Term Investments	139.2	46.2	3.2	-
Cash and Short Term Investments	191.4	108.7	63.7	90.9
Net Receivables	27.0	30.8	26.2	23.4
Inventory	3.0	4.7	4.0	3.6
Other Current Assets	12.5	12.3	9.2	8.5
Total Current Assets	233.9	156.5	103.1	126.3
Property, Plant & Equipment	4.9	6.3	4.7	4.5
Long Term Investments	-	-	0.4	0.3
Other Non-Current Assets	1.6	1.6	0.3	0.3
Total Non-Current Assets	6.5	7.9	5.3	5.1
Total Assets	240.4	164.4	108.4	131.4
Account Payables	3.1	5.1	4.0	4.3
Short Term Debt	-	24.4	21.0	32.2
Deferred Revenue	-	-	-	-
Other Current Liabilities	18.2	15.6	6.0	3.5
Total Current Liabilities	69.5	92.3	92.1	117.3
Long Term Debt	170.9	162.9	205.9	192.2
Other Non-Current Liabilities	133.5	88.5	25.3	9.8
Total Non-Current Liabilities	307.2	258.2	309.3	279.8
Total Liabilities	376.6	350.4	401.3	397.1
Common Stock	0.0	0.0	0.0	0.0
Retained Earnings	-1,487.0	-1,563.5	-1,759.5	-1,781.9
Total Stockholders Equity	-136.2	-186.0	-292.9	-265.6
Total Liabilities and Equity	240.4	164.4	108.4	131.4

Karyopharm Therapeutics Inc.(KPTI US)